SimAbs’ Continuous Manufacturing Platform Revolutionizes Biotherapeutics and Diagnostics Production
Diepenbeek, BioVille, Belgium, September 25, 2023 – SimAbs announces a successful capital raise of 1 million euro, marking a significant milestone in the company’s journey since its inception in 2019. This funding, primarily sourced from a consortium of renowned entrepreneurs and business angels affiliated with BAN Vlaanderen, is earmarked to facilitate the next phase of the company’s growth.
SimAbs’ groundbreaking technology is centered on continuous manufacturing, offering unparalleled advantages in cost-effectiveness, accelerated time to market, and enhanced quality. This fresh injection of funds will be channeled towards establishing a GMP facility, paving the way for the manufacturing of antibodies tailored for human applications.
Koen Dierckx, CEO of SimAbs, expressed his enthusiasm, stating, “We are immensely proud to have garnered the support of such a distinguished group of investors. This collaboration brings together the expertise of business angels from BAN Vlaanderen and several eminent Flemish entrepreneurs. A significant portion of this funding round was contributed by ABN Cleanroom, spearheaded by Jo Nelissen and Rosaline Wijnen. With Jo also being a recipient of the ‘Young Entrepreneur of the Year’ accolade, we are confident in the robust foundation we’ve established for SimAbs’ future endeavors.”
About SimAbs: Founded in 2019, SimAbs operates from its state-of-the-art labs and offices located in BioVille, Belgium. The company’s core focus lies in the research, development, and GMP manufacturing of antibodies. With a robust patent portfolio centered around its unique continuous manufacturing technology, SimAbs is on a mission to redefine bioprocessing. This aims to facilitate cost-effective, high-quality, and sustainable antibody manufacturing.
SimAbs offers a comprehensive range of services, including:
- Contract Development and Manufacturing for antibodies
- Cell line development
- USP/DSP development
- Analytical and formulation development
- Quality management and validation
- Project management
- Technology transfer to GLP/GMP manufacturing
- Regulatory affairs and clinical research
For further details or press inquiries, please: